Necrolytic migratory erythema. 2006

Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
Department of Dermatology and Allergology, Faculty of Medicine, University of Szeged, Hungary. kore@mail.szote.u-szegad.hu

BACKGROUND Necrolytic migratory erythema is considered to be a paraneoplastic dermatosis. The classical symptoms are associated with alpha-cell pancreatic islet cell tumor or 'glucagonoma'. Generally, extracutaneous hallmarks of this disease include weight loss, diabetes, anaemia and diarrhoea. METHODS We report a case of a 39-year-old woman with a 3-year history of recalcitrant psoriasiform eruption, who had no other associated symptoms on routine examination. Histologic examinations suggested necrolytic migratory erythema. Abdominal computer tomography was performed, which revealed a tumor in the tail of the pancreas. After distal resection of the pancreas her skin symptoms resolved in a few days time. Histology was consistent with glucagonoma. She is clinically well and symptomless and no signs of metastasis after 4 years. CONCLUSIONS It is infrequent to have only necrolytic migratory erythema, hyperglucagonaemia and islet-cell tumor but no other extracutaneous symptoms in glucagonoma syndrome. To our knowledge, ours is the second such case reported in the literature. Skin symptoms are important, often they are the clue to the diagnosis of glucagonoma syndrome.

UI MeSH Term Description Entries
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010257 Paraneoplastic Syndromes In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products. Paraneoplastic Syndrome,Syndrome, Paraneoplastic,Syndromes, Paraneoplastic
D004890 Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes. Erythemas
D005260 Female Females
D005935 Glucagonoma An almost always malignant GLUCAGON-secreting tumor derived from the PANCREATIC ALPHA CELLS. It is characterized by a distinctive migratory ERYTHEMA; WEIGHT LOSS; STOMATITIS; GLOSSITIS; DIABETES MELLITUS; hypoaminoacidemia; and normochromic normocytic ANEMIA. Adenoma, alpha-Cell,alpha-Cell Tumor,Glucagonoma Syndrome,Adenoma, alpha Cell,Adenomas, alpha-Cell,Glucagonoma Syndromes,Glucagonomas,Syndrome, Glucagonoma,Syndromes, Glucagonoma,Tumor, alpha-Cell,Tumors, alpha-Cell,alpha Cell Tumor,alpha-Cell Adenoma,alpha-Cell Adenomas,alpha-Cell Tumors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
October 2019, JAMA dermatology,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
December 1998, Revue medicale de Liege,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
March 2019, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
January 1981, Archives of dermatology,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
April 2003, Surgery,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
December 1979, Archives of dermatology,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
September 1992, Journal of the American Academy of Dermatology,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
November 2020, Medicina clinica,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
January 1984, Journal of the Royal Society of Medicine,
Réka K Kovács, and Irma Korom, and Attila Dobozy, and Gyula Farkas, and Jeno Ormos, and Lajos Kemény
June 2005, Revista espanola de enfermedades digestivas,
Copied contents to your clipboard!